MedWatch

Orphazyme CEO proud of "giant milestone"

Orphazyme CEO Anders Hinsby is proud of the company's approaching public listing, which will allow for the completion of four clinical trials – three of them in Phase III – and ensure approval for the company's main asset in 2020.

Foto: Henriette Dan Bonde/PR-foto

Danish biotech company Orphazyme is coming to the Copenhagen stock exchange.

An intention to float (ITF) announcement was submitted to the stock exchange on Tuesday morning last week, and with that, the company is heading towards its IPO at Nasdaq OMX Copenhagen by the end of 2017.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier